Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Wenjie Li, Yanjun Zhao, Hongjun Zhang, Wenying Zheng, Ruixuan Wang, Xing Gu
Summary: This study investigated the association between tumor mutational burden (TMB) and the therapeutic effect of Programmed Death 1/Programmed Death Ligand 1 inhibitors in non-small cell lung cancer. The results suggest that high TMB can serve as a potential predictive biomarker for improved progression-free survival and reduced overall response rate, but further investigation is needed to assess its predictive value in overall survival.
Review
Medicine, General & Internal
Dahui Yu, Chong Yuan, Hedan Zhang, Wenyan Chu
Summary: This meta-analysis assessed the relationship between tumor mutation burden (TMB) and the efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer (NSCLC) patients. The findings suggest that NSCLC patients with high TMB may benefit from immunotherapy, although TMB failed to predict overall survival benefits.
Review
Oncology
He Ba, Lei Liu, Qiang Peng, Jie Chen, Yao-Dong Zhu
Summary: This study indicates that the efficacy of PD-1/PD-L1 inhibitor therapy in patients with advanced NSCLC may vary depending on the bTMB level, with higher bTMB patients benefiting more from the treatment. However, due to various limitations, the results should be interpreted cautiously.
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan
Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Ana Bocanegra, Gonzalo Fernandez-Hinojal, Daniel Ajona, Ester Blanco, Miren Zuazo, Maider Garnica, Luisa Chocarro, Elvira Alfaro-Arnedo, Sergio Pineiro-Hermida, Pilar Morente, Leticia Fernandez, Ana Remirez, Miriam Echaide, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Alejandra Roncero, Carolina Gotera, Alfonso Ventura, Nerea Recalde, Jose G. Pichel, Juan Jose Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan
Summary: Recent studies show that baseline functional immunity is crucial for the success of immune checkpoint blockade therapies. In this study, high-dimensional systemic immune profiling was performed on non-small-cell lung cancer patients undergoing PD-L1/PD-1 blockade immunotherapy. Responders had a higher diversity of myeloid phenotypes in their peripheral blood. A diversity index was defined as a potential biomarker of response. Fractalkine (FKN), a chemokine linked to immune chemotaxis and adhesion, was identified as a biomarker of response and correlated with myeloid cell diversity. FKN inhibited lung adenocarcinoma growth in both human and mouse models through the involvement of systemic effector NK cells and increased tumor immune infiltration. FKN also sensitized mouse lung cancer models resistant to anti-PD-1 treatment to immunotherapy, indicating its potential therapeutic use in combination with immunotherapy.
Article
Oncology
Charlotte Margareta Brinch, Estrid Hogdall, Niels Junker, Holger Jon Moeller, Birgitte Sandfeld-Paulsen, Pieter de Heer, Luit Penninga, Philip Blach Rossen, Anders Krarup-Hansen, Ninna Aggerholm-Pedersen
Summary: This study investigates the prognostic value of plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) concentrations in patients with Gastrointestinal Stromal Tumor (GIST). The results show that the plasma concentrations of PD-1 and PD-L1 are associated with the activity of GIST, and high concentration of PD-L1 is related to poor prognosis.
Article
Oncology
Yoon Ah Cho, Hyunwoo Lee, Deok Geun Kim, Hyunjin Kim, Sang Yun Ha, Yoon-La Choi, Kee-Taek Jang, Kyoung-Mee Kim
Summary: Biomarkers like PD-L1 IHC, MSI, and TMB are used to predict response to immune checkpoint blockade (ICB). This study found significant associations between PD-L1 expression, TMB, and MSI scores, depending on the primary tumor site.
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Review
Oncology
Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni, Sheng Chen
Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yuan Li, Zuhua Chen, Weiping Tao, Nan Sun, Jie He
Summary: TMS18, a novel tumor mutation score, was found to be more accurate and efficient in predicting response to immunotherapy in NSCLC compared to TMB. Combined with PD-L1, TMS18 showed improved accuracy and efficiency in predicting response to ICIs, suggesting its potential as a promising biomarker in larger cohorts.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
D. J. McGrail, P. G. Pilie, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, A. B. Heimberger, B. Lim, N. T. Ueno, J. K. Litton, R. Ferrarotto, J. T. Chang, S. L. Moulder, S-Y Lin
Summary: Analysis of over 10,000 patient tumors from The Cancer Genome Atlas showed that TMB-H tumors had significantly higher response rates to immune checkpoint blockade in certain cancer types, while showing no significant benefit in others. These results do not support the use of TMB-H as a biomarker for ICB treatment across all solid cancer types, indicating the need for further tumor type-specific studies.
ANNALS OF ONCOLOGY
(2021)
Article
Cell Biology
Je-Jung Lee, So Young Kim, Songhee H. Kim, Seoyeon Choi, Bin Lee, Jeon-Soo Shin
Summary: In this study, the role of PD-L1 in cancer progression and its regulation of cancer prevention were investigated. It was found that PD-L1 depletion induced senescence in cancer cells by strongly inducing STING expression. Nuclear PD-L1 silencing increased STING promoter activity, indicating a negative regulation of STING expression by PD-L1 through transcriptional modulation. Furthermore, PD-L1 was shown to bind to the STING promoter region, directly controlling STING expression to promote cancer growth. Combining PD-L1 silencing with the senescence-inducing chemotherapeutic agent doxorubicin further enhanced the efficacy of PD-L1 targeting.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Caichen Li, Qihua He, Hengrui Liang, Bo Cheng, Jianfu Li, Shan Xiong, Yi Zhao, Minzhang Guo, Zhichao Liu, Jianxing He, Wenhua Liang
FRONTIERS IN ONCOLOGY
(2020)
Article
Medicine, Research & Experimental
Yongjing Zhang, Meng Shu, Wenhua Liang, Kun Jiang, Dianxin Zhang, Hong Qiu, Kaichun Wu
ADVANCES IN THERAPY
(2020)
Article
Biology
Shashuang Zhang, Wenhua Liang, Lingjie Luo, Shan Sun, Feng Wang
Editorial Material
Oncology
Jianrong Zhang, Meagan R. Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C. Brownson, Graham A. Colditz, Wenhua Liang, Jianxing He
BRITISH JOURNAL OF CANCER
(2020)
Article
Biochemistry & Molecular Biology
Kang Zhang, Xiaohong Liu, Jun Shen, Zhihuan Li, Ye Sang, Xingwang Wu, Yunfei Zha, Wenhua Liang, Chengdi Wang, Ke Wang, Linsen Ye, Ming Gao, Zhongguo Zhou, Liang Li, Jin Wang, Zehong Yang, Huimin Cai, Jie Xu, Lei Yang, Wenjia Cai, Wenqin Xu, Shaoxu Wu, Wei Zhang, Shanping Jiang, Lianghong Zheng, Xuan Zhang, Li Wang, Liu Lu, Jiaming Li, Haiping Yin, Winston Wang, Oulan Li, Charlotte Zhang, Liang Liang, Tao Wu, Ruiyun Deng, Kang Wei, Yong Zhou, Ting Chen, Johnson Yiu-Nam Lau, Manson Fok, Jianxing He, Tianxin Lin, Weimin Li, Guangyu Wang
Article
Critical Care Medicine
Ruchong Chen, Wenhua Liang, Mei Jiang, Weijie Guan, Chen Zhan, Tao Wang, Chunli Tang, Ling Sang, Jiaxing Liu, Zhengyi Ni, Yu Hu, Lei Liu, Hong Shan, Chunliang Lei, Yixiang Peng, Li Wei, Yong Liu, Yahua Hu, Peng Peng, Jianming Wang, Jiyang Liu, Zhong Chen, Gang Li, Zhijian Zheng, Shaoqin Qiu, Jie Luo, Changjiang Ye, Shaoyong Zhu, Xiaoqing Liu, Linling Chang, Feng Ye, Jinping Zheng, Nuofu Zhang, Yimin Li, Jianxing He, Shiyue Li, Nanshan Zhong
Article
Respiratory System
Zifeng Yang, Zhiqi Zeng, Ke Wang, Sook-San Wong, Wenhua Liang, Mark Zanin, Peng Liu, Xudong Cao, Zhongqiang Gao, Zhitong Mai, Jingyi Liang, Xiaoqing Liu, Shiyue Li, Yimin Li, Feng Ye, Weijie Guan, Yifan Yang, Fei Li, Shengmei Luo, Yuqi Xie, Bin Liu, Zhoulang Wang, Shaobo Zhang, Yaonan Wang, Nanshan Zhong, Jianxing He
JOURNAL OF THORACIC DISEASE
(2020)
Review
Respiratory System
Bo Cheng, Shan Xiong, Caichen Li, Hengrui Liang, Yi Zhao, Jianfu Li, Jiang Shi, Limin Ou, Zisheng Chen, Peng Liang, Wenhua Liang, Jianxing He
JOURNAL OF THORACIC DISEASE
(2020)
Article
Respiratory System
Fei Cui, Ke Xu, Hengrui Liang, Wenhua Liang, Jingpei Li, Wei Wang, Hui Liu, Jun Liu, Jianxing He
JOURNAL OF THORACIC DISEASE
(2020)
Editorial Material
Hematology
Tao Wang, Ruchong Chen, Chunli Liu, Wenhua Liang, Weijie Guan, Ruidi Tang, Chunli Tang, Nuofu Zhang, Nanshan Zhong, Shiyue Li
LANCET HAEMATOLOGY
(2020)
Article
Oncology
Hengrui Liang, Guo Lin, Wei Wang, Jun Huang, Yilin Yang, Yuting Lan, Runchen Wang, Fei Cui, Zhexue Hao, Hongsheng Deng, Shen Zhao, Bo Cheng, Shan Xiong, Jianfu Li, Caichen Li, Jun Liu, Jianxing He, Wenhua Liang
TRANSLATIONAL LUNG CANCER RESEARCH
(2020)
Article
Oncology
Zisheng Chen, Shan Xiong, Jianfu Li, Limin Ou, Caichen Li, Jinsheng Tao, Zeyu Jiang, Jianbing Fan, Jianxing He, Wenhua Liang
TRANSLATIONAL LUNG CANCER RESEARCH
(2020)
Article
Oncology
Hengrui Liang, Hongsheng Deng, Wenhua Liang, Kai Guo, Ziqing Gao, Ory Wiesel, Raja M. Flores, Kimberly Song, Bassam Redwan, Marcello Migliore, Shuben Li, Weiqiang Yin, Jianxing He
ANNALS OF TRANSLATIONAL MEDICINE
(2020)
Article
Oncology
Caichen Li, Jing Liao, Bo Cheng, Jianfu Li, Hengrui Liang, Yu Jiang, Zixuan Su, Shan Xiong, Feng Zhu, Yi Zhao, Ran Zhong, Feng Li, Jianxing He, Wenhua Liang
Summary: As age increases, the detection rates of pulmonary nodules and lung cancers also increase, but the proportion of stage I diseases in lung cancers decrease with higher starting age. Early lung cancer screening may be associated with a higher probability of identifying a curable disease.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Caichen Li, Huiting Wang, Yu Jiang, Wenhai Fu, Xiwen Liu, Ran Zhong, Bo Cheng, Feng Zhu, Yang Xiang, Jianxing He, Wenhua Liang
Summary: Lung cancer screening is burdened with physical and mental health issues for patients worldwide. This review summarizes recent studies on lung cancer screening from the US, Europe, and Asia, and discusses risk-based selection for screening, novel techniques for differential diagnosis of pulmonary nodules, and current strategies for suspected malignancy.
CANCER BIOLOGY & MEDICINE
(2022)